SciSparc

Company Overview

Snapshot

Founded in August 2004, SciSparc operates with 1–10 employees. The company has raised a total of $63.76 million across 12 funding rounds. SciSparc became public on NASDAQ in March 2017.

Business overview

SciSparc is a clinical-stage pharmaceutical company specializing in cannabinoid-based pharmaceuticals. The company focuses on developing drug programs utilizing THC and non-psychoactive cannabidiol (CBD) for central nervous system disorders. Its product pipeline includes SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for pain management; and SCI-210 for autism spectrum disorder and epilepsy. SciSparc operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceutical and medical biotechnology markets.

Strategic signal

In October 2025, SciSparc completed the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio. This strategic move signals a significant restructuring and consolidation of its pharmaceutical assets, potentially streamlining its drug development efforts and enhancing its market position by leveraging the acquired entity's public listing and operational infrastructure.

Company Intelligence Q&A

What was a significant recent corporate development for SciSparc?

In October 2025, SciSparc announced the closing of the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio.

What was the outcome of the N2OFF merger with SciSparc's subsidiary?

In October 2025, N2OFF completed its merger with SciSparc's majority-owned subsidiary MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.

What was a recent regulatory approval for SciSparc's Tourette syndrome treatment?

In September 2024, SciSparc secured FDA green light to launch its pivotal Phase IIb clinical trial for breakthrough Tourette Syndrome Treatment in the US.

What is SciSparc's involvement in quantum computing for drug discovery?

In October 2025, SciSparc resolved to launch an innovative quantum computing-enabled 3D protein modeling initiative to revolutionize AI drug discovery.

What was a recent patent granted to SciSparc?

In October 2023, SciSparc was granted a patent from the Australian Patent Office for its reduction of opioids use in pain management technology.